Quick Read – Moderna heads into Q2 earnings on a five-quarter beat streak, with traders pricing an 84% chance of another beat and a 0.12 put/call ratio. – BNTX shares Moderna’s ~$23B market cap but posted a 35% YoY revenue decline in Q1 while Moderna compounded its beat streak….
An August 5 FDA approval of mRNA-1010 would make Moderna a five-product company, rebuilding its respiratory franchise before the next flu season. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Moderna didn’t make the cut. Grab the names FREE today
Moderna (NASDAQ:MRNA) enters a critical six-day stretch with Q2 earnings due July 31, and an FDA decision on its seasonal flu vaccine expected August 5. Although the stock has already gained 83% in 2026, five consecutive earnings beats and a potential fifth commercial product give investors two major catalysts to watch. Moderna Has Beaten Earnings 5 Quarters in a Row Q1 2026 revenue landed at $389M against $236.36M consensus, a 64.58% beat on 263.6% YoY growth.
That extends a streak of five straight quarterly beats, with an average one-week post-earnings move of 5.26%. Polymarket traders are pricing an 84% probability Moderna beats again, and the July 31 expiration put/call ratio sits at just 0.12, one of the most call-skewed stocks ahead of earnings. An August 5 mRNA-1010 Approval Would Give Moderna Its Fifth Product An August 5 approval for mRNA-1010 (Moderna’s fifth commercial product, if cleared) rebuilds the respiratory franchise heading into the 2026 to 2027 flu season.